
Johnson & Johnson
JNJ 246.15 (0.11%) 0.28
Health Care
Pharmaceuticals
Quality Checklist 6/8
5Y Shares Out Change < 0%
ROIC > 10%
Debt/Equity < 1
Current Ratio > 1
Net Margin > 10%
Est. EPS Growth > 5%
Quick Ratio > 1
Past Net Income CAGR > 0%
0.0%of Portfolio
My holdings
Day change:
Total change:
Shares:Cost basis:
Market cap: $593.20(B)
EV: $620.40(B)
Total Equity: $81.54(B)
Earnings date: Apr-14-2026
P/E: 22.12
Forward P/E: 21.35
P/FCF: 30.09
P/S: 6.29
P/B: 7.27
EPS: $11.1
EPS (fwd): $11.5
FCF/share: $8.2
Revenue/share: $39.1
Book value/share: $33.9
ROIC: 21.7%
ROA: 13.5%
ROE: 33.6%
Debt/Equity: 0.60
Current Ratio: 1.00
Gross margin: 68.1%
Operating margin: 26.2%
Net margin: 28.5%
Dividend/share: $5.1
Div. yield: 2.09%
JNJ Valuation & Price Targets
Current Price
$246
Favorite Valuation Methods
More Valuation Methods
DCF (simple)
N/A
N/A
DCF (exit mult.)
N/A
N/A
DDM
N/A
N/A
EPS growth
N/A
N/A
Revenue growth
N/A
N/A
Peter Lynch FV
N/A
N/A
Graham No.
N/A
N/A
PEvaluation
21% overvalued
Low
$145
Mid
$194
High
$242
Current price
$246
Fair P/E
Margin of safety
EPS
Market Model
Economic moat: Wide
EPS Estimates
| Low | Avg | High | # | |
| FY+1 | 11.4 | 11.5 | 11.7 | 24 |
| FY+2 | 11.8 | 12.5 | 13.1 | 25 |
| FY+3 | 12.3 | 13.6 | 14.8 | 13 |
| FY+4 | 13.5 | 14.9 | 16.7 | 8 |
| FY+5 | 14.0 | 16.4 | 18.8 | 7 |
Analyst Price Targets
4% overvalued
Low
$155
Mid
$237
High
$265
Current price
$246
Analyst Recommendations
2-stage DCF
First Stage Duration: 5 Years | |
| Starting Free Cash Flow | |
First Stage Growth Rate | |
LowMidHigh | |
Terminal Growth Rate | |
LowMidHigh | |
| Discount Rate | |
Discounted Cash Flow
Forecast years: 5 Years | |
Terminal Growth Rate | |
LowMidHigh | |
| Discount Rate | |
Free cash flow estimates:
Discounted Cash Flow (exit mult.)
Forecast years: 5 Years | |
Exit FCF Multiple | |
LowMidHigh | |
| Discount Rate | |
Free cash flow estimates:
Dividend Discount Model
| Annual Dividend | |
First Stage Length (Years): 0 Years | |
| First Stage Growth Rate | |
| Final Growth Rate | |
| Discount Rate | |
EPS Growth
Forecast years: 5 Years | |
| Starting EPS | |
EPS Growth Rate | |
LowMidHigh | |
Final P/E | |
LowMidHigh | |
| Discount Rate | |
Revenue Growth Valuation
Forecast Years: 10 Years | |
| Base Revenue | |
Revenue Growth Rate | |
LowMidHigh | |
Final Net Margin | |
LowMidHigh | |
Final P/E Ratio | |
LowMidHigh | |
| Discount Rate | |
Peter Lynch Fair Value
| Earnings Per Share | |
| Growth Rate |
Graham Formula
| Earnings Per Share | |
| EPS Growth (7-10 years) | |
| Government Bond Rate |
